222 related articles for article (PubMed ID: 37289025)
21. Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.
Zhang T; Karsh LI; Nissenblatt MJ; Canfield SE
Clin Genitourin Cancer; 2020 Feb; 18(1):1-10. PubMed ID: 31653572
[TBL] [Abstract][Full Text] [Related]
22. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
Conteduca V; Jayaram A; Romero-Laorden N; Wetterskog D; Salvi S; Gurioli G; Scarpi E; Castro E; Marin-Aguilera M; Lolli C; Schepisi G; Maugeri A; Wingate A; Farolfi A; Casadio V; Medina A; Puente J; Vidal MJM; Morales-Barrera R; Villa-Guzmán JC; Hernando S; Rodriguez-Vida A; González-Del-Alba A; Mellado B; Gonzalez-Billalabeitia E; Olmos D; Attard G; De Giorgi U
Eur Urol; 2019 Mar; 75(3):368-373. PubMed ID: 30773204
[TBL] [Abstract][Full Text] [Related]
23. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
[TBL] [Abstract][Full Text] [Related]
24. Assessment of Total, PTEN
Di Lorenzo G; Zappavigna S; Crocetto F; Giuliano M; Ribera D; Morra R; Scafuri L; Verde A; Bruzzese D; Iaccarino S; Costabile F; Onofrio L; Viggiani M; Palmieri A; De Placido P; Marretta AL; Pietroluongo E; Luce A; Abate M; Navaeiseddighi Z; Caputo VF; Celentano G; Longo N; Ferro M; Morelli F; Facchini G; Caraglia M; De Placido S; Buonerba C
Clin Genitourin Cancer; 2021 Oct; 19(5):e286-e298. PubMed ID: 33958297
[TBL] [Abstract][Full Text] [Related]
25. siRNA-based approaches for castration-resistant prostate cancer therapy targeting the androgen receptor signaling pathway.
Yu Y; Papukashvili D; Ren R; Rcheulishvili N; Feng S; Bai W; Zhang H; Xi Y; Lu X; Xing N
Future Oncol; 2023 Sep; 19(30):2055-2073. PubMed ID: 37823367
[TBL] [Abstract][Full Text] [Related]
26. Improved therapeutic targeting of the androgen receptor: rational drug design improves survival in castration-resistant prostate cancer.
Lim AC; Attard G
Curr Drug Targets; 2013 Apr; 14(4):408-19. PubMed ID: 23565754
[TBL] [Abstract][Full Text] [Related]
27. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation pathway mediated by opioid receptor kappa 1.
Makino Y; Kamiyama Y; Brown JB; Tanaka T; Murakami R; Teramoto Y; Goto T; Akamatsu S; Terada N; Inoue T; Kodama T; Ogawa O; Kobayashi T
Commun Biol; 2022 Apr; 5(1):299. PubMed ID: 35365763
[TBL] [Abstract][Full Text] [Related]
29. Positive epigenetic regulation loop between AR and NSUN2 promotes prostate cancer progression.
Zhu W; Wan F; Xu W; Liu Z; Wang J; Zhang H; Huang S; Ye D
Clin Transl Med; 2022 Sep; 12(9):e1028. PubMed ID: 36169095
[TBL] [Abstract][Full Text] [Related]
30. Expansion of mouse castration-resistant intermediate prostate stem cells in vitro.
Xu Y; Mu J; Zhou Z; Leng Y; Yu Y; Song X; Liu A; Zhu H; Li J; Wang D
Stem Cell Res Ther; 2022 Jul; 13(1):299. PubMed ID: 35841025
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer.
He Y; Lu J; Ye Z; Hao S; Wang L; Kohli M; Tindall DJ; Li B; Zhu R; Wang L; Huang H
Nucleic Acids Res; 2018 Feb; 46(4):1895-1911. PubMed ID: 29309643
[TBL] [Abstract][Full Text] [Related]
32. Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.
Zhu Y; Sharp A; Anderson CM; Silberstein JL; Taylor M; Lu C; Zhao P; De Marzo AM; Antonarakis ES; Wang M; Wu X; Luo Y; Su N; Nava Rodrigues D; Figueiredo I; Welti J; Park E; Ma XJ; Coleman I; Morrissey C; Plymate SR; Nelson PS; de Bono JS; Luo J
Eur Urol; 2018 May; 73(5):727-735. PubMed ID: 28866255
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer.
Coleman IM; DeSarkar N; Morrissey C; Xin L; Roudier MP; Sayar E; Li D; Corey E; Haffner MC; Nelson PS
Clin Cancer Res; 2022 Jul; 28(14):3127-3140. PubMed ID: 35552660
[TBL] [Abstract][Full Text] [Related]
34. Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.
Mak B; Lin HM; Kwan EM; Fettke H; Tran B; Davis ID; Mahon K; Stockler MR; Briscoe K; Marx G; Zhang A; Crumbaker M; Tan W; Huynh K; Meikle TG; Mellett NA; Hoy AJ; Du P; Yu J; Jia S; Joshua AM; Waugh DJ; Butler LM; Kohli M; Meikle PJ; Azad AA; Horvath LG
BMC Med; 2022 Mar; 20(1):112. PubMed ID: 35331214
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer.
Kwan EM; Fettke H; Docanto MM; To SQ; Bukczynska P; Mant A; Pook D; Ng N; Graham LK; Mangiola S; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Horvath LG; Azad AA
Eur Urol Focus; 2021 Jan; 7(1):63-70. PubMed ID: 31103601
[TBL] [Abstract][Full Text] [Related]
36. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing.
Viswanathan SR; Ha G; Hoff AM; Wala JA; Carrot-Zhang J; Whelan CW; Haradhvala NJ; Freeman SS; Reed SC; Rhoades J; Polak P; Cipicchio M; Wankowicz SA; Wong A; Kamath T; Zhang Z; Gydush GJ; Rotem D; ; Love JC; Getz G; Gabriel S; Zhang CZ; Dehm SM; Nelson PS; Van Allen EM; Choudhury AD; Adalsteinsson VA; Beroukhim R; Taplin ME; Meyerson M
Cell; 2018 Jul; 174(2):433-447.e19. PubMed ID: 29909985
[TBL] [Abstract][Full Text] [Related]
37. Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer.
Loriot Y; Eymard JC; Patrikidou A; Ileana E; Massard C; Albiges L; Di Palma M; Escudier B; Fizazi K
Eur J Cancer; 2015 Sep; 51(14):1946-52. PubMed ID: 26208462
[TBL] [Abstract][Full Text] [Related]
38. Androgen Receptor and Beyond, Targeting Androgen Signaling in Castration-Resistant Prostate Cancer.
Reichert ZR; Hussain M
Cancer J; 2016; 22(5):326-329. PubMed ID: 27749325
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.
Karantanos T; Corn PG; Thompson TC
Oncogene; 2013 Dec; 32(49):5501-11. PubMed ID: 23752182
[TBL] [Abstract][Full Text] [Related]
40. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
